Bristol-Myers Squibb Co (NYSE:BMY) – Equities research analysts at Leerink Swann lifted their FY2018 earnings per share (EPS) estimates for shares of Bristol-Myers Squibb in a research note issued to investors on Tuesday. Leerink Swann analyst S. Fernandez now expects that the biopharmaceutical company will earn $3.10 per share for the year, up from their previous forecast of $3.07. Leerink Swann currently has a “Positive” rating and a $76.00 target price on the stock. Leerink Swann also issued estimates for Bristol-Myers Squibb’s FY2019 earnings at $3.26 EPS, FY2020 earnings at $3.57 EPS, FY2021 earnings at $3.64 EPS and FY2022 earnings at $4.27 EPS.
Other equities analysts also recently issued research reports about the company. Citigroup set a $72.00 price objective on Bristol-Myers Squibb and gave the stock a “buy” rating in a research report on Tuesday, December 5th. Zacks Investment Research upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $68.00 price objective on the stock in a research report on Wednesday, November 1st. SunTrust Banks upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research report on Monday, October 30th. Barclays lifted their price objective on Bristol-Myers Squibb from $58.00 to $65.00 and gave the stock an “equal weight” rating in a research report on Friday, October 13th. Finally, Jefferies Group downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $72.00 price objective on the stock. in a research report on Monday, October 16th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $65.58.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.67 by $0.01. The firm had revenue of $5.45 billion for the quarter, compared to analyst estimates of $5.35 billion. Bristol-Myers Squibb had a return on equity of 33.68% and a net margin of 4.85%. During the same period in the previous year, the company posted $0.63 earnings per share. The business’s revenue was up 3.9% on a year-over-year basis.
The firm also recently announced a quarterly dividend, which was paid on Thursday, February 1st. Shareholders of record on Friday, January 5th were given a $0.40 dividend. The ex-dividend date of this dividend was Thursday, January 4th. This represents a $1.60 dividend on an annualized basis and a yield of 2.51%. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s payout ratio is currently 271.19%.
In other Bristol-Myers Squibb news, EVP Sandra Leung sold 156,582 shares of Bristol-Myers Squibb stock in a transaction on Monday, December 4th. The stock was sold at an average price of $63.37, for a total value of $9,922,601.34. Following the sale, the executive vice president now owns 584,373 shares in the company, valued at $37,031,717.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Theodore R. Samuels II bought 4,000 shares of Bristol-Myers Squibb stock in a transaction on Friday, December 15th. The stock was acquired at an average price of $62.30 per share, for a total transaction of $249,200.00. Following the transaction, the director now directly owns 22,000 shares of the company’s stock, valued at $1,370,600. The disclosure for this purchase can be found here. 0.23% of the stock is owned by insiders.
A number of large investors have recently bought and sold shares of the business. Tradewinds Capital Management LLC raised its holdings in shares of Bristol-Myers Squibb by 34.6% in the 2nd quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 500 shares during the period. Delphi Private Advisors LLC purchased a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at $108,000. Atlantic Trust LLC purchased a new stake in shares of Bristol-Myers Squibb in the 2nd quarter valued at $111,000. Massey Quick Simon & CO. LLC raised its holdings in shares of Bristol-Myers Squibb by 523.5% in the 3rd quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 1,492 shares during the period. Finally, NuWave Investment Management LLC purchased a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at $119,000. Institutional investors own 69.70% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Analysts Issue Forecasts for Bristol-Myers Squibb Co’s FY2018 Earnings (BMY)” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.americanbankingnews.com/2018/02/08/analysts-issue-forecasts-for-bristol-myers-squibb-cos-fy2018-earnings-bmy.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.